STOCK TITAN

[SCHEDULE 13G] Alto Neuroscience, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Perceptive Advisors LLC, Perceptive Life Sciences Master Fund, Ltd. and Joseph Edelman disclosed a 7.3% beneficial ownership stake in Alto Neuroscience, Inc. (ticker ANRO), representing 1,989,393 shares of common stock. The filing states the ownership percentage is calculated from 27,076,629 outstanding shares as of August 8, 2025. The Master Fund directly holds the shares while Perceptive Advisors acts as investment manager and Mr. Edelman is the managing member, so each reporting person reports shared voting and dispositive power over the same block. The filing certifies the position is not held to change or influence control of the issuer.

Perceptive Advisors LLC, Perceptive Life Sciences Master Fund, Ltd. e Joseph Edelman hanno comunicato una partecipazione 7,3% di beneficiante in Alto Neuroscience, Inc. (ticker ANRO), che rappresenta 1,989,393 azioni ordinarie. La dichiarazione indica che la percentuale di proprietà è calcolata su 27,076,629 azioni in circolazione al 8 agosto 2025. Il Master Fund detiene direttamente le azioni mentre Perceptive Advisors agisce come gestore degli investimenti e il signor Edelman è il membro gestore, quindi ogni persona che segnala riferisce potere di voto e di disposizione condivisi sullo stesso blocco. La dichiarazione certifica che la posizione non è detenuta per modificare o influire sul controllo dell'emittente.

Perceptive Advisors LLC, Perceptive Life Sciences Master Fund, Ltd. y Joseph Edelman divulgan una participación del 7,3% en Alto Neuroscience, Inc. (ticker ANRO), que representa 1,989,393 acciones comunes. El escrito indica que el porcentaje de propiedad se calcula a partir de 27,076,629 acciones en circulación a partir del 8 de agosto de 2025. El Master Fund ostenta directamente las acciones mientras Perceptive Advisors actúa como administrador de inversiones y el Sr. Edelman es el miembro gerente, por lo que cada persona informante reporta poder de voto y disposición compartidos sobre el mismo bloque. El escrito certifica que la posición no se mantiene para cambiar o influir en el control del emisor.

Perceptive Advisors LLC, Perceptive Life Sciences Master Fund, Ltd. 및 Joseph Edelman은 Alto Neuroscience, Inc.의 7.3%의 유익한 소유 지분을 공개했습니다 (티커 ANRO), 이는 1,989,393주의 보통주를 나타냅니다. 공시에 의하면 소유 비율은 27,076,629 주의 발행 주식 중 남아 있는 주식 수를 기준으로 2025년 8월 8일에 계산됩니다. Master Fund는 주식을 직접 보유하고 있으며 Perceptive Advisors는 투자 관리자로서, Edelman 씨는 관리 구성원이며, 따라서 각 보고자는 동일 블록에 대해 의결 및 처분권을 공유합니다. 공시는 이 포지션이 발행인의 지배권을 바꾸거나 영향을 주기 위한 것이 아님을 인증합니다.

Perceptive Advisors LLC, Perceptive Life Sciences Master Fund, Ltd. et Joseph Edelman ont divulgué une participation bénéficiaire de 7,3% dans Alto Neuroscience, Inc. (ticker ANRO), représentant 1 989 393 actions ordinaires. Le dépôt indique que le pourcentage de propriété est calculé sur 27 076 629 actions en circulation au 8 août 2025. Le Master Fund détient directement les actions tandis que Perceptive Advisors agit en tant que gestionnaire d'investissement et M. Edelman est le membre gérant, de sorte que chaque personne déclarant déclare un pouvoir de vote et de disposition partagé sur le même bloc. Le dépôt certifie que la position n'est pas détenue dans le but de changer ou d'influencer le contrôle de l'émetteur.

Perceptive Advisors LLC, Perceptive Life Sciences Master Fund, Ltd. und Joseph Edelman haben eine 7,3%-Beteiligung an Alto Neuroscience, Inc. offengelegt (Wertpapierkennnummer ANRO), was 1.989.393 Stammaktien entspricht. Die Einreichung besagt, dass der Eigentumsanteil auf 27.076.629 ausstehende Aktien zum 8. August 2025 berechnet wird. Der Master Fund hält die Aktien direkt, während Perceptive Advisors als Investment-Manager fungiert und Herr Edelman der managing member ist, sodass jeder meldende Bestandteil gemeinschaftliche Stimm- und Verfügungsgewalt über denselben Block meldet. Die Einreichung bestätigt, dass die Position nicht dazu bestimmt ist, die Kontrolle des Emittenten zu verändern oder zu beeinflussen.

أعلنت Perceptive Advisors LLC و Perceptive Life Sciences Master Fund, Ltd. وجوزيف إدلمان عن ملكية فعّالة بنسبة 7.3% في Alto Neuroscience, Inc. (رمز التداول ANRO)، تمثل 1,989,393 سهماً من الأسهم العادية. وتذكر العريضة أن نسبة الملكية محسوبة من 27,076,629 سهماً مطروحة في التداول حتى تاريخ 8 أغسطس 2025. يحتفظ Master Fund بالأسهم بصورة مباشرة بينما تعمل Perceptive Advisors كمدير للاستثمار ويكون السيد إدلمان العضو المدير، لذا يبلغ كل مقدم تقرير عن سلطة التصويت والتصرف المشتركة على نفس الكتلة. تُ certifies العريضة أن الوضع ليس مُحتفظاً به لتغيير أو التأثير في سيطرة المُصدر.

Perceptive Advisors LLC、Perceptive Life Sciences Master Fund, Ltd. 与 Joseph Edelman 披露在 Alto Neuroscience, Inc. 的 7.3% 实益所有权股份,代表 1,989,393 股普通股。 filing 表明所有权百分比是基于 27,076,629 股在外流通股份于 2025年8月8日 的计算。 Master Fund 直接持有股份,而 Perceptive Advisors 担任投资经理,Edelman 先生为管理成员,因此每个报告人就同一区块报告 共同的投票与处置权。 filing 证明该头寸并非为改变或影响发行人的控制权而持有。

Positive
  • Material disclosure: Reporting of a 7.3% stake ensures regulatory transparency for investors
  • Single-block ownership: All reporting persons disclose the same 1,989,393 shares, reducing ambiguity about overlapping claims
Negative
  • No sole voting or dispositive power reported, indicating limited unilateral influence over corporate decisions
  • 7.3% stake may still exert market influence without a control intent, creating potential activist interest or trading volatility

Insights

Perceptive reports a material >5% passive stake and shared control of 1.99M shares.

The reported 1,989,393 shares equal 7.3% of the outstanding common stock based on 27,076,629 shares as of August 8, 2025, which meets the disclosure threshold requiring a Schedule 13G.

This position is described as shared voting and dispositive power and certified as not acquired to change control, indicating a likely passive or investment-management holding. Investors should note the holding is large enough to be a visible institutional stake but the filers disclaim a control intent in the near term.

Perceptive Advisors LLC, Perceptive Life Sciences Master Fund, Ltd. e Joseph Edelman hanno comunicato una partecipazione 7,3% di beneficiante in Alto Neuroscience, Inc. (ticker ANRO), che rappresenta 1,989,393 azioni ordinarie. La dichiarazione indica che la percentuale di proprietà è calcolata su 27,076,629 azioni in circolazione al 8 agosto 2025. Il Master Fund detiene direttamente le azioni mentre Perceptive Advisors agisce come gestore degli investimenti e il signor Edelman è il membro gestore, quindi ogni persona che segnala riferisce potere di voto e di disposizione condivisi sullo stesso blocco. La dichiarazione certifica che la posizione non è detenuta per modificare o influire sul controllo dell'emittente.

Perceptive Advisors LLC, Perceptive Life Sciences Master Fund, Ltd. y Joseph Edelman divulgan una participación del 7,3% en Alto Neuroscience, Inc. (ticker ANRO), que representa 1,989,393 acciones comunes. El escrito indica que el porcentaje de propiedad se calcula a partir de 27,076,629 acciones en circulación a partir del 8 de agosto de 2025. El Master Fund ostenta directamente las acciones mientras Perceptive Advisors actúa como administrador de inversiones y el Sr. Edelman es el miembro gerente, por lo que cada persona informante reporta poder de voto y disposición compartidos sobre el mismo bloque. El escrito certifica que la posición no se mantiene para cambiar o influir en el control del emisor.

Perceptive Advisors LLC, Perceptive Life Sciences Master Fund, Ltd. 및 Joseph Edelman은 Alto Neuroscience, Inc.의 7.3%의 유익한 소유 지분을 공개했습니다 (티커 ANRO), 이는 1,989,393주의 보통주를 나타냅니다. 공시에 의하면 소유 비율은 27,076,629 주의 발행 주식 중 남아 있는 주식 수를 기준으로 2025년 8월 8일에 계산됩니다. Master Fund는 주식을 직접 보유하고 있으며 Perceptive Advisors는 투자 관리자로서, Edelman 씨는 관리 구성원이며, 따라서 각 보고자는 동일 블록에 대해 의결 및 처분권을 공유합니다. 공시는 이 포지션이 발행인의 지배권을 바꾸거나 영향을 주기 위한 것이 아님을 인증합니다.

Perceptive Advisors LLC, Perceptive Life Sciences Master Fund, Ltd. et Joseph Edelman ont divulgué une participation bénéficiaire de 7,3% dans Alto Neuroscience, Inc. (ticker ANRO), représentant 1 989 393 actions ordinaires. Le dépôt indique que le pourcentage de propriété est calculé sur 27 076 629 actions en circulation au 8 août 2025. Le Master Fund détient directement les actions tandis que Perceptive Advisors agit en tant que gestionnaire d'investissement et M. Edelman est le membre gérant, de sorte que chaque personne déclarant déclare un pouvoir de vote et de disposition partagé sur le même bloc. Le dépôt certifie que la position n'est pas détenue dans le but de changer ou d'influencer le contrôle de l'émetteur.

Perceptive Advisors LLC, Perceptive Life Sciences Master Fund, Ltd. und Joseph Edelman haben eine 7,3%-Beteiligung an Alto Neuroscience, Inc. offengelegt (Wertpapierkennnummer ANRO), was 1.989.393 Stammaktien entspricht. Die Einreichung besagt, dass der Eigentumsanteil auf 27.076.629 ausstehende Aktien zum 8. August 2025 berechnet wird. Der Master Fund hält die Aktien direkt, während Perceptive Advisors als Investment-Manager fungiert und Herr Edelman der managing member ist, sodass jeder meldende Bestandteil gemeinschaftliche Stimm- und Verfügungsgewalt über denselben Block meldet. Die Einreichung bestätigt, dass die Position nicht dazu bestimmt ist, die Kontrolle des Emittenten zu verändern oder zu beeinflussen.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Perceptive Advisors LLC
Signature:/s/ Joseph Edelman
Name/Title:Joseph Edelman, Managing Member
Date:10/10/2025
Joseph Edelman
Signature:/s/ Joseph Edelman
Name/Title:Joseph Edelman
Date:10/10/2025
Perceptive Life Sciences Master Fund, Ltd.
Signature:/s/ Joseph Edelman
Name/Title:Joseph Edelman, Managing Member
Date:10/10/2025

FAQ

What stake did Perceptive report in Alto Neuroscience (ANRO)?

Perceptive Advisors, Perceptive Life Sciences Master Fund and Joseph Edelman each reported beneficial ownership of 1,989,393 shares, equal to 7.3% of outstanding common stock.

How was the 7.3% ownership percentage calculated?

The percentage is based on 27,076,629 outstanding shares of common stock as of August 8, 2025.

Does the filing indicate Perceptive seeks control of ANRO?

No. The certification states the securities were not acquired to change or influence control and no control intent is indicated.

Who holds voting and disposal power for the reported shares?

The Master Fund directly holds the shares; Perceptive Advisors and Joseph Edelman report shared voting and shared dispositive power over the same 1,989,393 shares.

When was the Schedule 13G signed?

The signatures are dated 10/10/2025.
Alto Neuroscienc

NYSE:ANRO

ANRO Rankings

ANRO Latest News

ANRO Latest SEC Filings

ANRO Stock Data

163.00M
24.80M
7.48%
64.06%
6.28%
Biotechnology
Pharmaceutical Preparations
Link
United States
MOUNTAIN VIEW